A pH-responsive High Density Lipoprotein-like Nanoparticle of Epothilone B

다국어 초록 (Multilingual Abstract)

Epothilone B (EpoB) is a paclitaxel (PTX)-like microtubule-stabilizing agent that induces mitotic arrest and apoptosis in cells. EpoB is a promising anti-tumor agent, and is thought to have the potential to overcome well-known PTX resistance. However, EpoB is barely soluble in water, and is fatal to normal cells due to extremely potent cytotoxicity. To reduce the unwanted cytotoxicity of EpoB to normal cells, a reconstituted highdensity lipoprotein (rHDL)-like nanoparticle of EpoB (EpoB-rHDL) was assembled using apolipoprotein A-I (apoA-I). The EpoB-rHDL, as well as PTX-rHDL (a HDLlike nanoparticle of paclitaxel), were indeed mild (nontoxic) to certain cell lines such as MCF7, MDA-MB-231, and SK-OV-3, while free EpoB and PTX were very toxic to those same cells. In contrast, the EpoB-rHDL and PTXrHDL were very effective in killing the Caco-2 and ZR-75- 1 while free drugs were less toxic to those cells. The susceptibility of cell lines to rHDLs was dependent on the expression of scavenger receptor class B type I (SR-BI), indicating that EpoB-rHDL selectively and efficiently kills only SR-BI-overexpressing cells. Furthermore, the EpoBrHDL released EpoB only at acidic pH, which may facilitate the escape of drugs from acidic endosome. Thus, EpoB-rHDL shown in this study enables safe and targeted delivery of the potent EpoB to cancer cells in SR-BIdependent manner.

참고문헌 (Reference)

1 Oh, K. T, "pH-sensitive properties of surface charge-switched multifunctional polymeric micelle" 376 : 134-140, 2009

2 Connor, J, "pH-sensitive liposomes:Acid-induced liposome fusion" 81 : 1715-1718, 1984

3 Gao, W, "pH-responsive nanoparticles for drug delivery" 7 : 1913-1920, 2010

4 Shen, Y, "pH-responsive nanoparticles for cancer drug delivery" 437 : 183-216, 2008

5 Shin, J. Y, "pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy" 7 : 2805-2816, 2012

6 Sepp-Lorenzino, L, "The microtubule-stabilizing agents epothilones A and B and their desoxyderivatives induce mitotic arrest and apoptosis in human prostate cancer cells" 2 : 41-52, 1999

7 Sparks, D. L, "The charge and structural stability of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles" 267 : 25839-25847, 1992

8 Shahzad, M. M, "Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles" 13 : 309-319, 2011

9 Mooberry, L. K, "Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier" 18 : 53-58, 2010

10 Lacko, A. G, "Prospects and challenges of the development of lipoproteinbased formulations for anti-cancer drugs" 4 : 665-675, 2007

11 Bae, Y, "Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy" 16 : 122-130, 2005

12 Senter, P. D, "Potent antibody drug conjugates for cancer therapy" 13 : 235-244, 2009

13 Holmes, F. A, "Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer" 83 : 1797-1805, 1991

14 Yu, D, "Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2kinase" 2 : 581-591, 1998

15 Fumoleau, P, "Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues" 18 : v9-v15, 2007

16 Ryan, R. O, "Nanobiotechnology applications of reconstituted high density lipoprotein" 8 : 28-37, 2010

17 Jin-Seol Kim, "Manufacturing and Shelf Stability of Reconstituted High-density Lipoprotein for Infusion Therapy" 한국생물공학회 16 (16): 785-792, 2011

18 Wahl, A. F, "Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis" 2 : 72-79, 1996

19 Ng, K. K, "Lipoprotein-inspired nanoparticles for cancer theranostics" 44 : 1105-1113, 2011

20 Paik, D, "Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro" 119 : 140-145, 2010

21 Lacko, A. G, "High density lipoprotein complexes as delivery vehicles for anticancer drugs" 22 : 2045-2049, 2002

22 Paramonov, S. E, "Fully aciddegradable biocompatible polyacetal microparticles for drug delivery" 19 : 911-919, 2008

23 McConathy, W. J, "Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel" 19 : 183-188, 2008

24 Forli, S, "Evaluation of novel epothilone analogues by means of a common pharmacophore and a QSAR pseudoreceptor model for taxanes and epothilone" 5 : 35-40, 2010

25 Areum Daseul Kim, "Dictyopteris undulata Extract Induces Apoptosis in Human Colon Cancer Cells" 한국생물공학회 19 (19): 419-425, 2014

26 Bae, Y, "Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change" 42 : 4640-4643, 2003

27 Lee, F. Y, "BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy" 7 : 1429-1437, 2001

28 Huang, R, "Apolipoprotein AI structural organization in high-density lipoproteins isolated from human plasma" 18 : 416-422, 2011

29 Sievers, E. L, "Antibody-drug conjugates in cancer therapy" 64 : 15-29, 2013

30 Kowalski, R. J, "Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®)" 272 : 2534-2541, 1997

31 Ganta, S, "A review of stimuli-responsive nanocarriers for drug and gene delivery" 126 : 187-204, 2008

32 Giannakakou, P, "A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells" 97 : 2904-2909, 1999